Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
China Marks WWII Defeat and Barclays Hacks Its Systems
47:12 - Bloomberg News Editor Pete Norman and Morgan Stanley Global Head of FX Strategy Hans Redeker review two stories from Bloomberg.com: ‘China Military Parade Sets Spin Machine Into Overdrive’ and ‘Barclays Hacks Its Own Systems to Find Holes Before Criminals Do’ with Guy Johnson and Anna Edwards on "Countdown."
  • Why the U.S. Dollar Bull Market Isn't Over Yet
  • Google Gives Logo a Huge Overhaul
  • What You Need to Know: China, Australia GDP, Oil